Slilaty Steve N. 4
4 · Sunshine Biopharma, Inc · Filed Jul 10, 2020
Insider Transaction Report
Form 4
Slilaty Steve N.
DirectorCEO and President10% Owner
Transactions
- Award
Common Stock
2019-10-20$0.00/sh+1,100,000$1,100→ 2,043,461 total - Award
Common Stock
2019-12-19$0.00/sh+1,300,000$1,300→ 3,343,461 total - Other
Common Stock
2019-12-31$0.00/sh+323,673$324→ 861,209 total(indirect: Held by TRT Pharma Inc., an entity controlled by the Reporting Person.)
Footnotes (2)
- [F1]The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person.
- [F2]Effective December 31, 2019, Advanomics Corporation, a entity controlled by the Reporting Person, effectuated a consolidation with 4019318 Canada, Inc., an entity controlled by the Chief Financial Officer of the Issuer. The resulting consoildated entity changed its name to TRT Pharma Inc. The consolidation resulted in the transfer of 323,673 shares of post-reverse splits of the Issuer's Common Stock to TRT Pharma Inc. of which the Reporting Person is a control person.